KW-0761 + Vorinostat
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cutaneous T-Cell Lymphoma
Conditions
Cutaneous T-Cell Lymphoma
Trial Timeline
Nov 1, 2012 → Feb 17, 2021
NCT ID
NCT01728805About KW-0761 + Vorinostat
KW-0761 + Vorinostat is a phase 3 stage product being developed by Kyowa Kirin for Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01728805. Target conditions include Cutaneous T-Cell Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01728805 | Phase 3 | Completed |
Competing Products
20 competing products in Cutaneous T-Cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONTAK (denileukin difitox, DAB389IL-2) | Eisai | Approved | 85 |
| ONTAK | Eisai | Approved | 85 |
| E7777 9 mcg/kg | Eisai | Phase 3 | 77 |
| ONTAK | Eisai | Approved | 85 |
| Mogamulizumab | Kyowa Kirin | Approved | 85 |
| Mogamulizumab + Brentuximab vedotin | Kyowa Kirin | Phase 1 | 33 |
| Mogamulizumab | Kyowa Kirin | Phase 2 | 52 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Comparator: vorinostat | Merck | Pre-clinical | 23 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| TR701 FA | Merck | Phase 2 | 52 |
| MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Aspirin + Ipilimumab + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Mogamulizumab | Merck | Phase 2 | 52 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 77 |
| Pimasertib + Dacarbazine | Merck | Phase 2 | 52 |